Jazz Pharmaceuticals will hold a minority equity interest in the new entity. Jazz Pharmaceuticals has signed a definitive agreement to purchase Actio Biosciences in a deal that includes an upfront payment of $820m and up to $500m in additional contingent payments. Jazz Pharmaceuticals plans to fund the acquisition with a combination of cash on hand and existing financing facilities. Financial advisor for Jazz Pharmaceuticals is Moelis & Company, with Hogan Lovells Cadwalader US serving as legal advisor. Actio Biosciences’ financial advisors are J.P. Morgan Securities and Centerview Partners, with legal counsel from Cooley.